After 30 days of treatment the analysis found that major bleeding - the most common complication with blood thinners - occurred at the same level (0.7%) for patients in both treatment groups A ...

Christian Ruff, MD, MPH, director of General Cardiology within the Cardiovascular Division at Brigham and Women’s Hospital and principal investigator of the AZALEA-TIMI 71 Study. The researchers found ...

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With ...

An increasing number of reports have surfaced regarding interpatient variability of the platelet inhibitor properties of the thienopyridine, clopidogrel. From these reports, it appears that patients ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

Abelacimab, an FXI inhibitor, significantly reduces bleeding risks in patients on antiplatelet therapy compared with rivaroxaban. The AZALEA-TIMI 71 study demonstrated consistent bleeding reduction ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

LOS ANGELES – Patients with diabetes had significantly higher adjusted risk of bleeding, cardiovascular-related death, and poorer net outcomes, particularly those treated with insulin, a subanalysis ...

Barcelona, Spain – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship ...

If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...